Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.

被引：0

作者：

Weber, Donna

Wang, Michael

Chen, Christine

Belch, Andrew

Stadtmauer, Edward A.

Niesvisky, Ruben

Yu, Zhinuan

Olesnyckyj, Marta

Zeldis, Jerome

Knight, Robert D.

Dimopoulos, Meletios

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX USA

[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Cornell Univ, Presbyterian Hosp, New York, NY USA

[6] Celgene Corp, Summit, NJ USA

[7] Univ Athens, Sch Med, Dept Therapeut, Kifisia, Greece

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3547

引用

页码：1012A / 1013A

页数：2

共 50 条

[41] OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY
Palumbo, A.
Moreau, P.
Dimopoulos, M. A.
Corradini, P.
Cavo, M.
Delforge, M.
Weisel, K. C.
Goldschmidt, H.
Petrini, M.
Kaiser, M. F.
Slaughter, A.
Simcock, M.
Herring, J.
Peluso, T.
Sternas, L.
Zaki, M.
Ocio, E. M.
HAEMATOLOGICA, 2015, 100 : 82 - 83
[42] Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide plus Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
Dimopoulos, Meletios A.
Palumbo, Antonio
Weisel, Katja
Ocio, Enrique M.
Cavo, Michele
Corradini, Paolo
Delforge, Michel
Oriol, Albert
Goldschmidt, Hartmut
Jesus Blanchard, Maria
Doyen, Chantal
Morgan, Gareth J.
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Peluso, Teresa
Sternas, Lars
Zaki, Mohamed H.
Moreau, Philippe
BLOOD, 2014, 124 (21)
[43] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
San Miguel, Jesus F.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine I.
Renner, Christoph
Bahlis, Nizar J.
Yu, Xin
Teasdale, Terri
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
BLOOD, 2013, 122 (21)
[44] Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study
Bahlis, Nizar
Samaras, Christy
Reece, Donna
Sebag, Michael
Matous, Jeffrey
Berdeja, Jesus
Shustik, Jesse
Schiller, Gary
Ganguly, Siddhartha
Song, Kevin
Seet, Christopher
Acosta-Rivera, Mirelis
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Liu, Hongjuan
Gentili, Christian
Siegel, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S162
[45] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Jian Hou
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Huisheng Ai
Jingshan Zhang
Honeylet Wortman-Vayn
Nianhang Chen
Jay Mei
Jianmin Wang
Journal of Hematology & Oncology, 6
[46] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Hou, Jian
Du, Xin
Jin, Jie
Cai, Zhen
Chen, Fangping
Zhou, Dao-bin
Yu, Li
Ke, Xiaoyan
Li, Xiao
Wu, Depei
Meng, Fanyi
Ai, Huisheng
Zhang, Jingshan
Wortman-Vayn, Honeylet
Chen, Nianhang
Mei, Jay
Wang, Jianmin
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
[47] Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial
van de Donk, Niels W. C. J.
Raab, Marc S.
Besemer, Britta
Siegel, David S.
Anwer, Faiz
Lipe, Brea
White, Darrell
Khan, Abdullah
Pianko, Matthew J.
Cheng, Yiming
Chen, Lu
Lin, Hongxia
Maciag, Paulo
Emerson, Joshua
Amin, Alpesh
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S191 - S192
[48] A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
Richardson, Paul G.
Jagannath, Sundar
Moreau, Philippe
Jakubowiak, Andrzej
Raab, Marc S.
Facon, Thierry
Vij, Ravi
White, Darrell J.
Reece, Donna
Benboubker, Lotfi
Zonder, Jeffrey A.
Deng, Wei
Kroog, Glenn
Singhal, Anil K.
Lonial, Sagar
BLOOD, 2012, 120 (21)
[49] Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Lopez, Joaquin Martinez
Chen, Christine I.
Spencer, Andrew
Knop, Stefan
Bahlis, Nizar J.
Renner, Christoph
Yu, Xin
Hong, Kevin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San Miguel, Jesus F.
BLOOD, 2013, 122 (21)
[50] PX-171-006: PHASE IB MULTICENTER DOSE ESCALATION STUDY OF CARFILZOMIB (CFZ) PLUS LENALIDOMIDE (LEN) AND LOW DOSE DEXAMETHASONE (LODEX) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) - PRELIMINARY RESULTS
Wang, M.
Gutierrez, A.
Niesvizky, R.
Bensinger, B.
Vallone, M.
Gutierrez, A. A.
Kauffman, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 431 - 431

← 1 2 3 4 5 →